The RAPID Coverage Pathway: FDA and CMS Move in Step for Breakthrough Devices
ALTAQ INSIGHTS |
REGULATORY AFFAIRS and REIMBURSEMENT
What the new same-day coverage process offers device makers, and how the procedure actually works from pre-IDE to National Coverage Determination
For years, the hardest part of bringing a Breakthrough Device to Medicare patients has not been the FDA review. It has been what comes after. A device could earn market authorization and then wait a year or more for a Medicare coverage decision, often while the sponsor generated a second evidence package to answer questions CMS had never been in the room to ask.
On April 23, 2026, CMS and FDA announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway to close that gap. On August 11, CMS published the procedural notice (CMS-3487-NC) in the Federal Register, with public comments due October 13, 2026. The idea is simple: bring CMS into the conversation at the IDE stage, agree on the clinical outcomes once, and issue a proposed National Coverage Determination (NCD) on the same day FDA authorizes the device.[1]
CMS Administrator Dr. Mehmet Oz put it plainly: the two agencies "work most effectively when aligned sooner in that process." FDA Commissioner Dr. Marty Makary described the agencies as "functioning as a single team to deliver life-saving Breakthrough Devices to American patients as soon as we know they work."[2]
The benefits: why RAPID matters to sponsors
• Coverage in months, not years. CMS posts the proposed NCD the day FDA authorizes the device, runs the statutory 30-day comment period, and targets a final NCD about 60 days after authorization for Class II devices and about 90 days for Class III. The agencies' own comparison is roughly two months versus a year or more today.[3]
One evidence package for two agencies. Because CMS helps define the clinical health outcomes before the IDE is submitted, the pivotal study that supports FDA authorization is designed from the outset to support coverage. That removes the most expensive feature of the old model: duplicative, post-authorization evidence generation.
An early read on the Medicare benefit category. CMS performs a preliminary benefit-category analysis before the kickoff meeting. It is not a final determination, but it flags the kind of structural coverage problem that has derailed products late in development.
A predictable, written signal from CMS. Once the IDE is approved, CMS states in writing its intent to issue a proposed NCD concurrently with FDA authorization. That is a materially stronger basis for financing, launch planning and payer conversations than anything the earlier Parallel Review or TCET programs offered.
Built for scale. TCET was capped at five devices a year and is now paused for new candidates. RAPID sets no numerical limit, and CMS says it will prioritize RAPID NCDs over the general NCD wait list if resources are constrained.
Faster access for beneficiaries. Medicare patients are enrolled in the pivotal trial, and the population that generated the evidence is the population that gets coverage first.
Two caveats belong next to the benefits. RAPID is not automatic coverage: the NCD remains subject to public comment and CMS discretion, and if the evidence supports the device but leaves gaps, CMS can issue a Coverage with Evidence Development (CED) NCD instead of full coverage. And in vitro diagnostics are excluded, which matters to many of the companies we work with. IVD sponsors should keep watching the docket and consider commenting.[4]
Who is eligible
A device must meet all of the following at the time it enters the pathway:
FDA Breakthrough Device designation.
Class II devices must be in FDA's Total Product Life Cycle Advisory Program (TAP) and headed for De Novo; Class III devices must be headed for PMA (TAP participation is optional).
The device is at the IDE pre-submission stage, with a plan to enroll Medicare beneficiaries. Products already past that point are not eligible.
Nothing immediately makes clear that the device falls outside a Medicare benefit category; no existing NCD controls it; and it is separately payable by Medicare.
It is not an IVD and is not otherwise excluded by statute or regulation.
The procedure: three stages, two agencies, one study
The pathway follows the device from pre-IDE engagement through the final coverage determination. The figure below maps every step to the agency that owns it, and the table that follows shows what FDA, CMS and the sponsor each do at every stage.
Figure 1. The RAPID coverage pathway, from pre-IDE engagement to the final NCD. FDA steps at left, CMS steps at right; the proposed NCD posts on the same day as FDA market authorization.
Stage | What happens (FDA/CMS/sponsor) | What the sponsor gets |
Pre-IDE | Manufacturer contacts FDA's TAP team after Breakthrough designation. FDA and CMS confirm eligibility; CMS runs a preliminary benefit-category analysis. Kickoff meeting with FDA, CMS and the sponsor to agree clinical outcomes. Formal written feedback from both agencies through a TAP amendment or Sprint discussion. | Outcomes that satisfy both the premarket review and the coverage analysis, before a single patient is enrolled. |
Formal IDE | Sponsor submits the IDE protocol with the agreed outcomes and Medicare enrollment plan. FDA reviews and approves the IDE, issuing any study design considerations; it shares its decision letter with CMS. CMS confirms the design and states its intent to issue a proposed NCD concurrently with market authorization. Sponsor runs the study. | One pivotal study, one evidence package, and a written signal from CMS about where coverage is heading. |
Transition to coverage | Sponsor files the marketing submission (De Novo or PMA) plus a short NCD request cover letter. FDA shares the final study report with CMS. On the day FDA grants authorization, CMS posts the proposed NCD and opens a 30-day comment period. Final NCD roughly 60 days (Class II) or 90 days (Class III) after authorization. If evidence gaps remain, CMS may issue a Coverage with Evidence Development NCD and reconsider it later for full coverage. | National Medicare coverage in about two to three months instead of a year or more. |
A few procedural details are worth underlining. Entry is through FDA, not CMS: the sponsor emails FDA's TAP team after Breakthrough designation, and FDA loops CMS in. The IDE protocol is the document both agencies act on, so the outcomes language in it should be written with a coverage reader in mind. The sponsor can withdraw at any point before the proposed NCD is issued. And the NCD request cover letter, filed alongside the marketing submission, is what formally triggers the same-day proposal, so it should be prepared well ahead of the FDA decision.
What to do now
If you have a Breakthrough-designated device approaching an IDE pre-submission, RAPID should be on the agenda for that Q-Sub. Three actions are worth taking before the pathway goes live: audit your pipeline for devices that meet the eligibility criteria, especially Class II candidates that are not yet in TAP; build Medicare enrollment and CMS-relevant outcomes into study design now, since a protocol that lacks them cannot be retrofitted into the pathway; and comment on CMS-3487-NC by October 13 on the points that affect you, whether that is the IVD exclusion, the pre-submission cutoff or the CED provisions.
AltaQ has led IDE, De Novo and PMA programs for more than thirty years, and our clinical and regulatory teams already work in the pre-submission meetings where RAPID decisions will be made. We do not just advise you on what to do; we work with you to get the device approved and, now, covered. If you would like to talk through whether a product in your pipeline is a RAPID candidate, contact us! https://www.altaq.com/contact; info@altaq.com
Sources
[1] Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway, 91 FR 51710 (Aug. 11, 2026) (a proposed NCD “will be released on the same day as FDA market authorization”); see also CMS and FDA joint press announcement, Apr. 23, 2026.
[2] CMS and FDA press releases, Apr. 23, 2026 (statements of CMS Administrator Mehmet Oz and FDA Commissioner Marty Makary).
[3] CMS, CMS-3487-NC procedural notice fact sheet (final NCD goal of approximately 60 days after FDA market authorization for Class II devices and 90 days for Class III); CMS and FDA press announcement, Apr. 23, 2026 (coverage “as soon as two months after market authorization”).
[4] 91 FR 51710 (Aug. 11, 2026); CMS-3487-NC fact sheet (in vitro diagnostic tests are not eligible and continue under existing Medicare coverage pathways). Comments due Oct. 13, 202
Comments